aTyr Pharma Inc. announced that Sanuj Ravindran, M.D., has joined the company as Chief Business Officer. Dr. Ravindran will lead aTyr's corporate development and strategy efforts, including the planning and execution of strategic growth initiatives as the company advances its mission to make meaningful medicines for patients with serious diseases. In Dr. Ravindran's most recent role as Senior Vice President and Global Head, Corporate Development at The Medicines Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | +1.32% |
|
+0.65% | +9.22% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.22% | 105M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- ATYR Stock
- News aTyr Pharma, Inc.
- ATyr PharmaAppoints Sanuj Ravindran, M.D., as Chief Business Officer